This point remains valid. Modern evidence clarifies differences between their targets and the contribution of metabolism to effects.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Studies altering CYP2D6 activity show that shifts in the balance of DXM and DXO change the profile of subjective responses. Xiao’s paper compares target binding in vitro.
Limits of the conclusion: Each substance’s contribution depends on exposure and the study endpoint. Binding data concern the biological system studied; their relevance to effects in humans remains uncertain.
The main pathway is described correctly. Conversion rates vary with genetic variants of the enzyme and drug inhibition.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Capon’s pharmacokinetic study and Rüdesheim’s model link CYP2D6 activity to DXM exposure. Zawertailo’s studies also examine subjective effects.
Limits of the conclusion: Interpretation depends on formulation, concomitant medicines and the measure being examined.
With reduced CYP2D6 activity, DXM exposure can increase substantially. The experience also changes: a small study reported greater sedation, dysphoria and psychomotor impairment.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Capon examined pharmacokinetics in poor and extensive metabolizers; Zawertailo’s pilot study compared their subjective and psychomotor responses.
Limits of the conclusion: The finding applies to the conditions of these small studies. Genotype accounts for part of the variability, while individual responses also depend on other factors.
Modern terminology distinguishes PM, IM, NM and UM: poor, intermediate, normal and ultrarapid metabolism. Functional activity of variants and the effects of medicines on actual enzyme activity are considered.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Caudle’s consensus standardizes translation of CYP2D6 genotype into phenotype; Rüdesheim’s model applies modern categories to DXM pharmacokinetics.
Limits of the conclusion: The historical label EM requires checking the definition used in the particular study. Enzyme inhibitors can alter the functional phenotype, a process called phenoconversion.
A modern scheme also includes DXO glucuronidation. Results should distinguish unconjugated DXO, total DXO and the protein-unbound fraction.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Lutz’s paper examines how CYP-dependent and subsequent pathways affect assessment of metabolism; Rüdesheim’s model accounts for processing of DXM and DXO.
Limits of the conclusion: The meaning of a measurement depends on the analytical method. Concentrations can be compared after identifying which form of the substance was measured.